Threshold Pharmaceuticals, Inc (THLD)
http://www.thresholdpharm.com/
Company Address:
1300 Seaport Boulevard, Suite 500
Redwood City, CA 94063
605.474.8200
CIK: 0001183765
Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.
Management: http://www.thresholdpharm.com/sec/management
http://www.thresholdpharm.com/sec/tumor_hypoxia
Clinical Pipeline: http://www.thresholdpharm.com/sec/clinical_pipeline
Product Pipeline:
TH-302 is a hypoxia-activated prodrug (HAP) for the potential treatment of solid tumors. TH-302, which was discovered at Threshold, is a novel drug candidate that is activated under the metabolic conditions typical of cancer cells. We filed an IND (Investigational New Drug) with the FDA in April 2007 and started a Phase 1 clinical trial in July 2007. We initiated a second clinical trial of TH-302 in August 2008. This Phase 1/2 clinical trial is also focused on treating solid tumors.
Glufosfamide has been investigated for the potential treatment of pancreatic cancer, small cell lung cancer, platinum-resistant ovarian cancer and advanced soft tissue sarcoma. The soft tissue sarcoma trial provided evidence of clinical activity. Additionally, in a phase 2 clinical trial of glufosfamide in combination with gemcitabine for the treatment of advanced pancreatic cancer, the data indicated that glufosfamide plus gemcitabine may benefit patients with chemotherapy naive pancreatic cancer. The Company will be seeking a partner to continue development of glufosfamide in cancer.
2-Deoxyglucose, or 2DG, for the treatment of solid tumors, has been evaluated in a Phase 1 clinical trial alone and in combination with Taxotere.
Recent News:
http://finance.yahoo.com/q/h?s=THLD+Headlines
Filings: http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001183765&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
Transfer Agent:
Mellon Investor Services LLC
85 Challenger Road
Ridgefield Park, NJ 07660
800.356.2017
BNYMellon Shareowner Services
Share Structure:
Outstanding Shares
33,702,242 as of Oct 31, 2010
Authorized Shares
150,000,000 as of Sep 30, 2010
Preferred Shares Authorized
2,000,000 as of Sep 30, 2010
No Preferreds Issued or Outstanding as of Sep 30, 2010
Investor Relations:
Denise T. Powell
Threshold Pharmaceuticals
650.474.8206
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
